SANA Stock Analysis: Buy, Sell, or Hold?
SANA - Sana Biotechnology, Inc. Common Stock
$2.68
-0.09 (-3.25%)
▼
5d:
-14.1%
30d:
-36.34%
90d:
-39.23%
HOLD
MODERATE Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 14, 2026
Smart Money Accumulation
SANA is down 17.5% this week, but smart money is accumulating calls. Top strike: $5 2026-04-17 with 4,427 OI. Call ratio: 100% View Scanner →
Strength: 10.0/10
Get Alerted When SANA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SANA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: SANA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: SANA is currently trading at $2.68, which is considered oversold relative to its 30-day fair value range of $2.98 to $3.97.
Technical Outlook: Technically, SANA is in a uptrend. The price is currently testing key support at $2.66. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: SANA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $8.43 (+214.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SANA is in a uptrend. The price is currently testing key support at $2.66. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: SANA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $8.43 (+214.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$2.98 -
$3.97
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.2%)
- BULLISH: Trading 214.5% below Wall St target ($8.43)
- CAUTION: 5-day price weakness (-14.1%) - monitor closely
Fair Price Analysis
30-Day Fair Range
$2.98 -
$3.97
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$2.66
Resistance Level
$3.33
Current Trend
Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.39
Wall Street Target
$8.43
(+214.5%)
Share & Embed Analysis
Last updated: March 30, 2026 6:23 PM ET
Data refreshes hourly during market hours. Next update: 7:23 PM
Data refreshes hourly during market hours. Next update: 7:23 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SANA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$89 | 54 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 56 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1018 | 61 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 51 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 50 HOLD |
